GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Tribute Pharmaceuticals Canada Inc (OTCPK:TBUFF) » Definitions » Beneish M-Score

Tribute Pharmaceuticals Canada (Tribute Pharmaceuticals Canada) Beneish M-Score : 0.00 (As of Apr. 29, 2024)


View and export this data going back to . Start your Free Trial

What is Tribute Pharmaceuticals Canada Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

The historical rank and industry rank for Tribute Pharmaceuticals Canada's Beneish M-Score or its related term are showing as below:

During the past 13 years, the highest Beneish M-Score of Tribute Pharmaceuticals Canada was 0.00. The lowest was 0.00. And the median was 0.00.


Tribute Pharmaceuticals Canada Beneish M-Score Historical Data

The historical data trend for Tribute Pharmaceuticals Canada's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tribute Pharmaceuticals Canada Beneish M-Score Chart

Tribute Pharmaceuticals Canada Annual Data
Trend Dec05 Dec06 Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.28 12.99 -1.82 -2.99 -0.68

Tribute Pharmaceuticals Canada Quarterly Data
Dec10 Mar11 Jun11 Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.41 -0.68 -1.88 -1.28 -0.79

Competitive Comparison of Tribute Pharmaceuticals Canada's Beneish M-Score

For the Drug Manufacturers - Specialty & Generic subindustry, Tribute Pharmaceuticals Canada's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Tribute Pharmaceuticals Canada's Beneish M-Score Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Tribute Pharmaceuticals Canada's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Tribute Pharmaceuticals Canada's Beneish M-Score falls into.



Tribute Pharmaceuticals Canada Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Tribute Pharmaceuticals Canada for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 1.9476+0.528 * 0.7464+0.404 * 2.6681+0.892 * 1.5786+0.115 * 0.7029
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.7752+4.679 * -0.00689-0.327 * 1.5592
=-0.76

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Sep15) TTM:Last Year (Sep14) TTM:
Total Receivables was $5.57 Mil.
Revenue was 6.79 + 5.199 + 4.432 + 4.742 = $21.16 Mil.
Gross Profit was 4.262 + 3.305 + 2.825 + 3.012 = $13.40 Mil.
Total Current Assets was $18.95 Mil.
Total Assets was $84.90 Mil.
Property, Plant and Equipment(Net PPE) was $0.96 Mil.
Depreciation, Depletion and Amortization(DDA) was $3.24 Mil.
Selling, General, & Admin. Expense(SGA) was $11.17 Mil.
Total Current Liabilities was $31.52 Mil.
Long-Term Debt & Capital Lease Obligation was $11.36 Mil.
Net Income was 1.19 + -7.085 + -4.106 + -0.832 = $-10.83 Mil.
Non Operating Income was 2.172 + -5.758 + -3.331 + -1.081 = $-8.00 Mil.
Cash Flow from Operations was -0.243 + -1.431 + -2.093 + 1.517 = $-2.25 Mil.
Total Receivables was $1.81 Mil.
Revenue was 3.514 + 3.731 + 3.146 + 3.015 = $13.41 Mil.
Gross Profit was 1.707 + 1.884 + 1.562 + 1.185 = $6.34 Mil.
Total Current Assets was $29.01 Mil.
Total Assets was $41.98 Mil.
Property, Plant and Equipment(Net PPE) was $0.93 Mil.
Depreciation, Depletion and Amortization(DDA) was $1.10 Mil.
Selling, General, & Admin. Expense(SGA) was $9.12 Mil.
Total Current Liabilities was $6.66 Mil.
Long-Term Debt & Capital Lease Obligation was $6.94 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(5.565 / 21.163) / (1.81 / 13.406)
=0.262959 / 0.135014
=1.9476

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(6.338 / 13.406) / (13.404 / 21.163)
=0.472773 / 0.63337
=0.7464

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (18.945 + 0.961) / 84.903) / (1 - (29.005 + 0.932) / 41.983)
=0.765544 / 0.286926
=2.6681

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=21.163 / 13.406
=1.5786

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(1.104 / (1.104 + 0.932)) / (3.243 / (3.243 + 0.961))
=0.54224 / 0.771408
=0.7029

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(11.165 / 21.163) / (9.124 / 13.406)
=0.527572 / 0.680591
=0.7752

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((11.358 + 31.522) / 84.903) / ((6.943 + 6.656) / 41.983)
=0.505047 / 0.323917
=1.5592

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-10.833 - -7.998 - -2.25) / 84.903
=-0.00689

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Tribute Pharmaceuticals Canada has a M-score of -0.76 signals that the company is likely to be a manipulator.


Tribute Pharmaceuticals Canada Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Tribute Pharmaceuticals Canada's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Tribute Pharmaceuticals Canada (Tribute Pharmaceuticals Canada) Business Description

Traded in Other Exchanges
N/A
Address
Tribute Pharmaceuticals Canada Inc was incorporated under the Business Corporations Act (Ontario) on November 14, 1994. The Company is a specialty pharmaceutical company. It conducts acquisition, licensing, development and promotion of healthcare products in Canada. It sells Uracyst and NeoVisc internationally through a number of strategic partnerships. The Company's portfolio of assets includes nine product lines, eight of which are on the market in Canada, including: NeoVisc, NeoVisc Single Dose, Uracyst, BladderChek, Bezalip SR, Soriatane, Cambia, Daraprim, Collatamp G, and MycoVa. The Company markets its products in Canada through its own sales force and currently has licensing agreements for the distribution of select products in over 20 countries, and continues to expand this footprint. It faces product competition from companies marketing competing pharmaceutical products and medical devices in Canada. The Company's operations are or may be subject to various federal, provincial, state and local laws, regulations and recommendations relating to the marketing of products and relationships with treating physicians, data protection, safe working conditions, laboratory and manufacturing practices, the export of products to certain countries and the purchase, storage, movement, use and disposal of hazardous or potentially hazardous substances.
Executives
John M Gregory director, 10 percent owner
Sj Strategic Investments Llc 10 percent owner
Joan P Gregory other: Member 340 EDGEMONT AVE., SUITE 500, BRISTOL TN 37620
James M Gregory other: Member 340 EDGEMONT AVE., SUITE 500, BRISTOL TN 37620
Susan Gregory other: Member 340 MARTIN LUTHER KING, JR. BLVD, SUITE 200, BRISTOL TN 37620

Tribute Pharmaceuticals Canada (Tribute Pharmaceuticals Canada) Headlines

No Headlines